Filing Details

Accession Number:
0000899243-21-018276
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-04 13:00:00
Reporting Period:
2021-05-01
Accepted Time:
2021-05-04 21:39:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1466301 Clovis Oncology Inc. CLVS Pharmaceutical Preparations (2834) 900475355
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1650504 Lindsey Rolfe C/O Clovis Oncology, Inc.
5500 Flatiron Parkway, Suite 100
Boulder CO 80301
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-01 3,749 $0.00 73,113 No 4 M Direct
Common Stock Disposition 2021-05-04 2,015 $5.54 71,098 No 4 S Direct
Common Stock Acquisiton 2021-05-01 4,625 $0.00 75,723 No 4 M Direct
Common Stock Disposition 2021-05-04 2,486 $5.54 73,237 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-05-01 3,749 $0.00 3,749 $0.00
Common Stock Restricted Stock Units Disposition 2021-05-01 4,625 $0.00 4,625 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,245 No 4 M Direct
50,875 No 4 M Direct
Footnotes
  1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  2. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
  3. On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
  4. On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
  5. This transaction was executed in multiple trades at prices ranging from $5.53 to $5.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.